



ESUR17

24th Meeting of the EAU Section of Urological Research

In collaboration with the EAU Section of Uro-pathology **esup**

12-14 October 2017, Paris, France

www.esur17.org

esur

EAU
European
Association
of Urology

Preliminary Scientific Programme

Thursday, 12 October 2017

13.00 – 14.30	Registration
14.30 – 14.40	Opening Yves Allory, Paris (FR) Meeting Chair Kerstin Junker, Homburg (DE) ESUR Chair Rodolfo Montironi, Ancona (IT) ESUP Chair
14.40 – 15.55	Session 1 Tumour complexity 1: Microenvironment
14.40 – 15.05	The role of nerves in cancer progression Claire Magnon, Paris (FR)
15.05 – 15.30	The role of tumour microenvironment for drug resistance Arne Östman, Stockholm (SE)
15.30 – 15.55	Immune cells: Role in tumour progression Thorwald van Hall, Leiden (NL)
15.55 – 16.20	Break
16.20 – 17.25	Session 2 Tumour complexity 2: Immune system
16.20 – 16.45	Immune scoring system in modern pathology: A new grading system? G. Netto, Baltimore (US)
16.45 – 17.05	Response prediction for checkpoint inhibitors: More than target testing Emanuela Romano, Paris (FR)
17.05 – 17.25	Immune checkpoint blockade: Future prospects Stephen Tait, Glasgow (GB)
17.25 – 18.25	Short presentations 1

Friday, 13 October 2017

- 08.30 – 09.35** **Session 3**
Tumour complexity 3: Model systems
- 08.30 – 08.50** **In-vitro model systems: Organotypic tumour slice culture**
Geertje van der Horst, Leiden (NL)
- 08.50 – 09.15** **PDX models for investigation of resistance mechanisms in bladder and kidney cancer**
Thierry Massfelder, Strasbourg (FR)
- 09.15 – 09.35** **Organ on a chip**
Anja van de Stolpe, Eindhoven (NL)
- 09.35 – 10.35** **Short presentations 2**
- 10.35 – 11.00** **Break**
- 11.00 -12.25** **Session 4**
Tumour heterogeneity in bladder cancer
- 11.00 – 11.20** **Tumour heterogeneity of FGFR3 mutations in invasive bladder cancer: Implications for perioperative anti-FGFR3 treatment**
Bas van Rhijn, Amsterdam (NL)
- 11.20 – 11.45** **Clonal evolution and potential therapeutic targets in urothelial carcinoma**
Lars Dyrskjøt, Aarhus (DK)
- 11.45 – 12.05** **Urothelial carcinoma variants and molecular subtypes**
Antonio Lopez-Beltran, Lisbon (PT)
- 12.05 - 12.25** **How bladder cancer heterogeneity matters for the urologist?**
Evangelos Xylinas, Paris (FR)
- 12.25 – 13.30** **Lunch**
- 13.30 – 15.00** **Poster session 1**
- 15.00 – 16.35** **Session 5**
DNA repair mechanisms
- 15.00 – 15.25** **DNA repair mechanisms: Role in disease development and treatment**
Dik van Gent, Rotterdam (NL)
- 15.25 – 15.45** **Defects in DNA repair genes: Role in chemotherapy response in urological cancers**
David Liu, Cambridge (US)
- 15.45 -16.10** **The molecular rationale for PARP1 inhibitor function**
Felix Feng, San Francisco (US)
- 16.10 – 16.35** **DNA repair in prostate cancer: Biology and clinical implications**
Joaquin Mateo, London (GB)
- 16.35 – 17.00** **Break**
- 17.00 – 18.00** **Short presentations 3**

Saturday, 14 October 2017

08.45 – 09.35	Session 6 CRISPR
08.45 – 09.10	CRISPR: New technical perspectives in research and treatment Rogier Louwen, Rotterdam (NL)
09.10 – 09.35	CRISPR for high throughput functional cancer genomics in mice Roland Rad, Munich (DE)
09.35 – 10.15	Short presentations 4
10.15 – 10.45	Break
10.45 – 11.45	Session 7 ARTP: Prostate cancer
11.45 – 12.15	Short presentations 5
12.15 – 12.45	T.b.c.
12.45 – 13.45	Lunch
13.45 – 15.15	Poster session 2
15.00 – 15.30	Break
15.30 – 16.20	Session 8 Liquid biopsies: Extracellular vesicles
15.30 – 15.55	Isolation techniques An Hendrix, Ghent (BE)
15.55 – 16.20	EVs and therapy Lorraine O'Driscoll, Dublin (IE)
16.20 – 16.40	Short presentations 6
16.40 – 17.00	Awards and closing remarks